- Home
- OMCL vs NRIX Comparison
OMCL vs NRIX Comparison
Compare OMCL & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | NRIX |
|---|---|---|
| Founded | 1992 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.7B |
| IPO Year | 2001 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OMCL | NRIX |
|---|---|---|
| Price | $46.27 | $16.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $51.50 | $29.46 |
| AVG Volume (30 Days) | 525.2K | ★ 1.3M |
| Earning Date | 02-05-2026 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,177,740,000.00 | $83,980,000.00 |
| Revenue This Year | $8.61 | N/A |
| Revenue Next Year | $4.30 | $20.16 |
| P/E Ratio | $109.75 | ★ N/A |
| Revenue Growth | 10.67 | ★ 53.95 |
| 52 Week Low | $22.66 | $8.18 |
| 52 Week High | $55.00 | $22.50 |
Technical Indicators
Market Signals| Indicator | OMCL | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 39.80 |
| Support Level | $45.10 | $16.15 |
| Resistance Level | $50.14 | $17.50 |
| Average True Range (ATR) | 1.72 | 1.10 |
| MACD | -0.80 | -0.32 |
| Stochastic Oscillator | 18.25 | 11.87 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.